SUBSCRIBE
SUBSCRIBE

C4 Therapeutics

NEWS
Booming C4 Therapeutics to Move Out of Pricey Kendall Square Next Year
Business
What You Need to Know About C4 Therapeutics
January 3, 2017
 · 
6 min read
Load More
AWARDS
  • NextGen Class of 2017
JOBS
IN THE PRESS
Press Releases
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - January 26, 2026
January 27, 2026
 · 
1 min read
Press Releases
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
January 15, 2026
 · 
10 min read
Press Releases
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
November 26, 2025
 · 
1 min read
Press Releases
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 6, 2025
 · 
13 min read
Press Releases
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
October 17, 2025
 · 
6 min read
Press Releases
C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma
October 1, 2025
 · 
5 min read
Press Releases
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
September 22, 2025
 · 
12 min read
Press Releases
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
September 4, 2025
 · 
4 min read
Press Releases
C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting
September 3, 2025
 · 
3 min read
Press Releases
C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
August 7, 2025
 · 
11 min read
Load More